On May 19, 2022 Scandion Oncology (Scandion) reported its interim report for Q1 2022 (Press release, Scandion Oncology, MAY 19, 2022, View Source;interim-report-q1-2022,c3570190 [SID1234614846]). The following is taken from the report.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Bo Rode Hansen, President and CEO, comments
"It is with pleasure that we report on our activities for the first quarter of 2022. It has been a good start to the year with solid operations, continued execution of our strategy and implementation of our plans. I am looking at a company "punching above its weight" in several ways."
On January 12, Scandion Oncology announced that Mads Kronborg, bringing more than a decade of corporate communication and investor relations experience in the global life-science industry, will now help plan and drive its external communication as Head of External Communication.
On January 18, Scandion Oncology announced that data with the Company’s lead compound SCO-101 as combination therapy in patients with metastatic colorectal cancer was accepted for poster presentation at the ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium.
On February 2, Scandion Oncology announced approval from the German and Spanish regulatory authorities to expand part 2 of the CORIST Phase II study to Germany and Spain.
Highlights after the end of the period
On May 11, Scandion Oncology enhances management and clinical development function with appointment of global executive as Chief Medical Officer. Dr. Alfredo Zurlo brings decades of experience from clinical development in oncology.
The interim report Q1 2022 is available on the Company’s website: www.scandiononcology.com.
Today at 10:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update.
At the end of the presentation there will be a Q&A session.
Access to the event can be obtained as follows:
REPLAY access:
Webcast replay will be available at www.scandiononcology.com in the Investors section and at www.financialhearings.com
The information was provided by the contact person above for publication on May 19, 2022, at 08.30 CET.